Press Releases
- Positive results from Active Biotech’s clinical phase I LION study to be presented at AAO 2025 in October
- INTERIM REPORT Q2 2025
- Active Biotech provides status update of its development programs
- Interview with investigators of laquinimod eye drop study LION now available on Active Biotech’s website
- Results from tasquinimod study in heavily pretreated patients with relapsed refractory multiple myeloma presented at ASCO 2025 available on Active Biotech’s website